Wave Life Sciences touts Huntington's disease win in Phase 1b/2a trial

Max Gelman

Senior Editor

Wave Life Sciences said Tuesday that its experimental Huntington’s disease therapy effectively lowered the mutant huntingtin protein (mHTT) levels associated with the disease in a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Wave Life Sciences touts Huntington's disease win in Phase 1b/2a trial

Max Gelman

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

The Endpoints 11 winners: Big bets on AI, new frontiers in editing, a neuro renaissance and Chinese chemistry

Novo Nordisk to decrease some insulin pen manufacturing, transition supply

Exclusive: J&J folds cardiovascular and metabolic drug unit

FDA approves Dupixent in COPD, opening ‘next chapter’ for Sanofi and Regeneron’s bestseller

FDA approves Bristol Myers and Karuna's schizophrenia drug, in milestone for psychiatry

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships

Wave Life Sci­ences touts Hunt­ing­ton's dis­ease win in Phase 1b/2a tri­al

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Wave Life Sciences touts Huntington's disease win in Phase 1b/2a trial